Literature DB >> 33313072

Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country.

Jesús K Yamamoto-Furusho1, Germán E Sánchez-Morales1.   

Abstract

BACKGROUND AND AIM: Ulcerative colitis (UC) is a subtype of inflammatory bowel disease that can develop extraintestinal manifestations (EIMs) in a subgroup of patients. The aim of this work was to study the frequency and clinical factors associated with the development of EIMs.
METHODS: We evaluated a total of 260 Mexican patients with confirmed UC who were followed retrospectively in order to identify the factors associated with the presence of EIMs.
RESULTS: The frequency of EIM was 55.8%. The factors associated with the development of EIM were pancolitis (p = 0.003, OR = 2.44, 95% CI = 1.34-4.56) and previous colectomy (p = 0.024, OR = 7.54, 95% CI = 1.20-60.44). A clinical course of initial activity and then long remission for >5 years was found to be a protective factor (p = 0.002, OR = 0.31, 95% CI = 0.14-0.67).
CONCLUSION: The frequency of EIM was 55.8% in our population, and the factors associated with their development were pancolitis and colectomy; meanwhile, a clinical course of initial activity and then long remission was a protector feature.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Extraintestinal manifestations; Inflammatory bowel disease; Ulcerative colitis

Year:  2020        PMID: 33313072      PMCID: PMC7706485          DOI: 10.1159/000510070

Source DB:  PubMed          Journal:  Inflamm Intest Dis        ISSN: 2296-9365


  25 in total

1.  The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study).

Authors:  Ø Palm; B Moum; J Jahnsen; J T Gran
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

Review 2.  Extraintestinal manifestations of inflammatory bowel disease.

Authors:  S Ardizzone; P Sarzi Puttini; A Cassinotti; G Bianchi Porro
Journal:  Dig Liver Dis       Date:  2008-07       Impact factor: 4.088

Review 3.  Cutaneous manifestations of gastrointestinal disease: part II.

Authors:  Breck Thrash; Mahir Patel; Kejal R Shah; C Richard Boland; Alan Menter
Journal:  J Am Acad Dermatol       Date:  2013-02       Impact factor: 11.527

4.  Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease.

Authors:  T R Orchard; S Thiyagaraja; K I Welsh; B P Wordsworth; J S Hill Gaston; D P Jewell
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

5.  Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history.

Authors:  T R Orchard; B P Wordsworth; D P Jewell
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

Review 6.  The joint-gut axis in inflammatory bowel diseases.

Authors:  Lianne K P M Brakenhoff; Désirée M van der Heijde; Daniel W Hommes; Tom W J Huizinga; Herma H Fidder
Journal:  J Crohns Colitis       Date:  2009-11-30       Impact factor: 9.071

7.  Clinical patterns of familial inflammatory bowel disease.

Authors:  J Satsangi; C Grootscholten; H Holt; D P Jewell
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

Review 8.  Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease.

Authors:  Udayakumar Navaneethan; Bo Shen
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

9.  Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.

Authors:  K de Vlam; H Mielants; C Cuvelier; F De Keyser; E M Veys; M De Vos
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

10.  Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study.

Authors:  Elena Ricart; Remo Panaccione; Edward V Loftus; William J Tremaine; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2004-05       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.